Currently, the only validated companion diagnostic test for first-line immunotherapy in patients with metastatic NSCLC is the expression of programmed death ligand 1 (PD-L1) in tumor tissue [18]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.